Identification of Optimal Stimulation Site for Cervical Dystonia Symptoms: An Exploratory Study
- Conditions
- Spasmodic TorticollisCervical Dystonia
- Interventions
- Device: rTMS
- Registration Number
- NCT01859247
- Lead Sponsor
- University of New Mexico
- Brief Summary
The overall objective of this application is to therapeutically target the dysfunctional premotor-motor interaction in dystonia-and to provide a focused treatment of specific anatomical networks in order to reduce side effects and to improve symptom control over conventional therapies.
- Detailed Description
We propose using repetitive transcranial magnetic stimulation (rTMS) over distinct premotor areas in patients with cervical dystonia (CD) with the goal of improving symptoms and reducing unwanted side effects. The knowledge gained in this proposed research will identify a specific premotor area to be targeted with rTMS that is expected to result in a novel intervention that could enhance or replace current treatments for CD. rTMS could be included as an adjunct treatment to botulinum toxin that could sustain treatment effect and decrease the frequency of re-injection, potentially resulting in cost savings without a decrease in symptom control. In addition to medical cost reduction, improved quality of life could be expected with the successful development of therapies that extend dystonia symptom control. rTMs has been FDA-approved for the treatment of depression and our proposal uses an even lower stimulation rate, suggesting continued use within clearly safe parameters. Successful completion of this research could lead to rapid adoption of this therapeutic modality.
We will test the hypothesis that rTMS of a distinct premotor site will provide more effective treatment of CD than non-specific activation of the entire premotor region. This will be done by performing a randomized, observer-blinded exploratory pilot study to determine the optimal site of rTMS over various sites of the premotor and motor cortex to improve the symptoms of cervical dystonia. Completion of this aim should lead to development of targeted TMS therapy for CD.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 8
- Clinical diagnosis of idiopathic cervical dystonia
- Age 18 years or older
- Normal findings in the medical history, physical and neurological examination, except for dystonia
- Last treatment with botulinum toxin more than two months ago
- History of seizure disorder
- Pregnancy- a pregnancy test will be performed for women of childbearing potential
- History of any other neurological disorders or conditions requiring the use of anti-depressants that are known to increase seizure threshold, neuroleptic medication, anticholinergic drugs and muscle relaxants
- History of neuroleptic medications/ prior use of neuroleptics
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Sham rTMS rTMS 0.2 Hz rTMS for 15 minutes Primary motor cortex rTMS rTMS 0.2 Hz rTMS for 15 minutes Supplemental Motor Area rTMS rTMS 0.2 Hz rTMS for 15 minutes Anterior Cingulate rTMS rTMS 0.2 Hz rTMS for 15 minutes Dorsal Premotor rTMS rTMS 0.2 Hz rTMS for 15 minutes
- Primary Outcome Measures
Name Time Method Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) Change from baseline pre-intervention TWSTRS score to post-intervention within 1 hour of treatment Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) was used to assess severity of disease. The score for this section ranges from 0 (absence of severity) to 35 (maximum severity).
- Secondary Outcome Measures
Name Time Method Dorsal Premotor-motor Inhibition (dPMI) Change from baseline dPMI to post-intervention within 1 hour of treatment Composite Measure of Patient Rating of Symptoms and Tolerability Assessment completed immediately after rTMS treatment session This measure will confirm the intervention tolerability by the patient. He/she scored the tolerability from 0-10, 0 being "completely tolerable" and 10 "completely intolerable."
Trial Locations
- Locations (1)
University of New Mexico
🇺🇸Albuquerque, New Mexico, United States